Your browser does not support JavaScript or it may be disabled!
rediff.com
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
NEWS ON MOBILE
Get Realtime News
on your webpage

About 15 results for "eli lilly"

Aurobindo receives USFDA approval to manufacture ADHD drug

Atomoxetine capsules are the AB rated generic equivalent of Eli Lilly and Company's Strattera capsules. DNA, 1 month ago

131 images for eli lilly

Mideast Time, 5 months ago
American Banking News, 5 months ago
CNBC, 5 months ago
Post Online Media, 5 months ago
Post Online Media, 5 months ago
Live Trading News, 5 months ago
WKRB News, 5 months ago
Post Online Media, 5 months ago
American Banking News, 5 months ago
American Banking News, 5 months ago

UK Supreme Court rules in favor of Lilly's Alimta patents

(Reuters) - Eli Lilly and Co won a years-long patent dispute with Actavis on Friday after the UK Supreme Court ruled that the generic drugmaker's versions of Lilly's top-selling cancer drug Alimta directly infringe on certain Lilly patents in Britain, France, ...
 Reuters2 weeks ago
Money Control

Billions saved because FDA didn't rush approval of Alzheimer's drug

The U.S. Food and Drug Administration's decision not to rush approval for Eli Lilly's experimental Alzheimer's treatment solanezumab - a drug that turned out to be ineffective - may have saved American taxpayers as much as $100 billion over the past four ...
 Reuters2 months ago Aurobindo Pharma gets USFDA nod to make attention deficit disorder drug  Business Standard1 month ago Glenmark gets USFDA nod for ADHD drug  Business Standard1 month ago

Lilly migraine treatment meets main goal in late-stage studies

Eli Lilly and Co said on Friday patients with episodic and chronic migraine reported fewer debilitating headaches after using the drugmaker's experimental drug compared to those on placebo. About 40 million Americans suffer from migraines, and the disease ...
 Reuters2 months ago Lilly reports positive interim data on breast cancer combo drug  Reuters2 months ago

Profit profile helps Lilly shares rebound from Alzheimer's setback

Shares of Eli Lilly & Co have staged a dramatic rebound following massive disappointment for its experimental Alzheimer's medicine late last year, outperforming rivals as investors warm to the drugmaker's profit outlook. Investors are counting on Lilly's ...
 Reuters2 months ago

Sensex Finishes Flat; M&M; Surges 3.4% on Strong Q4 Results

Posted by Equitymaster Indian share markets continued to trade flat during the afternoon session. At the closing bell, the BSE Sensex stood lower by 14 points, while the NSE Nifty finished down by 4 points. Meanwhile, the S&P BSE Mid Cap and the S&P BSE Small ...
 Equitymaster.com1 month ago

Sensex Trades on a Volatile Note; Pharma Stocks Gain

Posted by Equitymaster After opening the day negative, Indian share markets witnessed volatile activity and are currently trading flat with a positive bias. Sectoral indices are trading on a mixed note, with stocks in the pharma sector and the IT sector ...
 Equitymaster.com1 month ago
Money Control

Lupin launches erectile dysfunction drug Cialis

Domestic pharma major Lupin Ltd today launched erectile dysfunction treatment medicine Cialis in India through an exclusive licensing pact with Eli Lilly. Lupin has acquired the rights to market, promote and distribute Lilly's erectile dysfunction (ED) ...
 Business Standard2 months ago Lupin gains after launching erectile dysfunction drug  Business Standard2 months ago
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
1.
2.
3.
4.
5.
6.
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts

Get

Realtime News

on your Webpage

Add Widget >Get your members hooked!
    
Alerts
Get updated on latest news & your favorite topics right in your inbox!
 
More     Less